Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher24/7 Wall Street • 10/15/26
Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?24/7 Wall Street • 10/15/26
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to makeCNBC • 10/14/26
Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industryWSJ • 10/13/26
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma banBusiness Insider • 10/13/26
‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocksMarket Watch • 10/13/26
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/13/26
Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026Accesswire • 10/13/26
Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?The Motley Fool • 10/13/26
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer VaccinesZacks Investment Research • 10/12/26
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?The Motley Fool • 10/12/26
Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?The Motley Fool • 10/10/26
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up24/7 Wall Street • 10/09/26
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?The Motley Fool • 10/08/26